Humanized Anti-Factor D Antibodies And Uses Thereof
US-2015376295-A1 · Dec 31, 2015 · US
Therapeutic factor VIII antibodies
US9062115B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9062115-B2 |
| Application number | US-201113822952-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 15, 2011 |
| Priority date | Sep 22, 2010 |
| Publication date | Jun 23, 2015 |
| Grant date | Jun 23, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to therapeutic FVIII antibodies. In particular, the present invention relates to FVIII antibodies having the ability to prolong the circulatory half life of FVIII. The present invention furthermore relates to use of such antibodies in treatment and prophylaxis of haemophilia A.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for treating haemophilia A comprising administering, to a patient in need thereof, a monoclonal Factor VIII antibody having the ability to bind to activated human Factor VIII, wherein said antibody, upon binding to activated Factor VIII, reduces dissociation of the A2 domain, wherein said antibody does not interfere with von Willebrand Factor (vWF) binding, wherein the light chain of said monoclonal antibody contains CDR1 of SEQ ID NO:11, CDR2…
Assignees
Inventors
Classifications
Chemistry & Metallurgy · mapped topic
Human Necessities · mapped topic
Chemistry & Metallurgy · mapped topic
Human Necessities · mapped topic
Chemistry & Metallurgy · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9062115B2 cover?
- The present invention relates to therapeutic FVIII antibodies. In particular, the present invention relates to FVIII antibodies having the ability to prolong the circulatory half life of FVIII. The present invention furthermore relates to use of such antibodies in treatment and prophylaxis of haemophilia A.
- Who is the assignee on this patent?
- Oestergaard Henrik, Hilden Ida, Holmberg Heidi Lindgreen, and 3 more
- What technology area does this patent fall under?
- Primary CPC classification C07K16/36. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jun 23 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).